Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03663335




Registration number
NCT03663335
Ethics application status
Date submitted
4/06/2018
Date registered
10/09/2018
Date last updated
13/06/2022

Titles & IDs
Public title
Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients
Scientific title
A Partially-blinded, Active-controlled, Multicenter, Randomized Study Evaluating Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in de Novo and Maintenance Kidney Transplant Recipients (CIRRUS I)
Secondary ID [1] 0 0
2017-003607-22
Secondary ID [2] 0 0
CCFZ533A2201
Universal Trial Number (UTN)
Trial acronym
CIRRUS I
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Kidney Transplant Rejection 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - CFZ533 - MMF - CS
Treatment: Drugs - Tacrolimus - MMF - +/- corticosteroids

Experimental: Arm 1/Cohort 1 - CFZ533 dose A+ MMF + Corticosteroids

Experimental: Arm 2/Cohort 1 - CFZ533 dose B + MMF + Corticosteroids

Active Comparator: Arm 3/Cohort 1 - Control/Standard of Care: TAC + MMF + Corticosteroids

Experimental: Arm 1/Cohort 2 - CFZ533 dose C + MMF ± Corticosteroids

Active Comparator: Arm 2/Cohort 2 - Tac + MMF ± Corticosteroids


Other interventions: CFZ533 - MMF - CS
Comparison with standard of care immunosuppression

Treatment: Drugs: Tacrolimus - MMF - +/- corticosteroids
Standard of care immunosupprevive regimen
Intervention code [1] 0 0
Other interventions
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Proportion of patients with composite event (BPAR, Graft Loss or Death)
Timepoint [1] 0 0
Month 12
Secondary outcome [1] 0 0
Cohorts 1 and 2-Mean eGFR over 12 months
Timepoint [1] 0 0
Baseline to month 12
Secondary outcome [2] 0 0
Cohorts 1 and 2-Cohorts 1 and 2-safety of CFZ533 regimens compared to a tacrolimus based regimen
Timepoint [2] 0 0
Baseline to month 12
Secondary outcome [3] 0 0
Cohorts 1 and 2-Cohorts 1 and 2 - tolerability of CFZ533 regimens compared to a tacrolimus based regimen
Timepoint [3] 0 0
Baseline to month 12
Secondary outcome [4] 0 0
Cohorts 1 and 2-pharmacokinetics of CFZ533 during the 60 months treatment period and explore the dose-exposure relationship
Timepoint [4] 0 0
Baseline to month 60
Secondary outcome [5] 0 0
Cohorts 1 and 2-immunogenicity of CFZ533 during the 60 months treatment period
Timepoint [5] 0 0
Baseline to month 60

Eligibility
Key inclusion criteria
- Written informed consent obtained before any assessment.

- Male or female patient = 18 years old.

- Up to date vaccination as per local immunization schedules.

- Recipients of a kidney transplant

- Recipients of a primary kidney transplant from a heart-beating deceased, living
unrelated or non-HLA identical living related donors.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Multi-organ transplant recipients or prior kidney transplant.

- Recipients of an organ from a non-heart beating donor.

- Recipient of an organ from an HLA identical living related donor.

- ABO incompatible or complement-dependent lymphocytotoxic (CDC) crossmatch positive
transplant

- Recipients of kidneys from donors who are older than 65 years.

- Recipients of kidneys from donors with terminal serum creatinine > 2 mg/dL.

- Patients at high immunological risk for rejection

- Patient who is anti-HIV positive, HBsAg-positive or anti-HCV positive (without proof
of sustained viral response (SVR) after anti-HCV treatment).

- Recipient of a kidney from a donor who tests positive for HIV, HBsAg/HBc positive or
HCV.

- A negative Epstein Barr virus (EBV) test.

- Evidence of advanced liver disease (Child-Pugh C), or any sign of liver
decompensation.

- Patient with severe systemic infections, current or within the two weeks prior to
randomization.

- History of malignancy of any organ system, treated or untreated, within the past 5
years, regardless of whether there is evidence of local recurrence or metastases, with
the exception of localized excised non-melanomatous skin lesions.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
28/11/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
29/10/2021
Sample size
Target
Accrual to date
Final
418
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Recruitment hospital [1] 0 0
Novartis Investigative Site - Camperdown
Recruitment hospital [2] 0 0
Novartis Investigative Site - Adelaide
Recruitment hospital [3] 0 0
Novartis Investigative Site - Clayton
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
5000 - Adelaide
Recruitment postcode(s) [3] 0 0
3168 - Clayton
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Illinois
Country [4] 0 0
United States of America
State/province [4] 0 0
Kansas
Country [5] 0 0
United States of America
State/province [5] 0 0
Maryland
Country [6] 0 0
United States of America
State/province [6] 0 0
Massachusetts
Country [7] 0 0
United States of America
State/province [7] 0 0
Michigan
Country [8] 0 0
United States of America
State/province [8] 0 0
Missouri
Country [9] 0 0
United States of America
State/province [9] 0 0
North Carolina
Country [10] 0 0
United States of America
State/province [10] 0 0
Ohio
Country [11] 0 0
United States of America
State/province [11] 0 0
Texas
Country [12] 0 0
United States of America
State/province [12] 0 0
Washington
Country [13] 0 0
Argentina
State/province [13] 0 0
Buenos Aires
Country [14] 0 0
Argentina
State/province [14] 0 0
Cordoba
Country [15] 0 0
Argentina
State/province [15] 0 0
Corrientes
Country [16] 0 0
Belgium
State/province [16] 0 0
Leuven
Country [17] 0 0
Brazil
State/province [17] 0 0
RS
Country [18] 0 0
Brazil
State/province [18] 0 0
SP
Country [19] 0 0
Canada
State/province [19] 0 0
British Columbia
Country [20] 0 0
Czechia
State/province [20] 0 0
Prague 4
Country [21] 0 0
France
State/province [21] 0 0
Bordeaux Cedex
Country [22] 0 0
France
State/province [22] 0 0
Creteil
Country [23] 0 0
France
State/province [23] 0 0
Grenoble
Country [24] 0 0
France
State/province [24] 0 0
Lyon
Country [25] 0 0
France
State/province [25] 0 0
Nantes Cedex 1
Country [26] 0 0
France
State/province [26] 0 0
Paris cedex 15
Country [27] 0 0
France
State/province [27] 0 0
Toulouse Cedex 4
Country [28] 0 0
France
State/province [28] 0 0
Tours
Country [29] 0 0
Germany
State/province [29] 0 0
Bavaria
Country [30] 0 0
Germany
State/province [30] 0 0
Berlin
Country [31] 0 0
Germany
State/province [31] 0 0
Dresden
Country [32] 0 0
Germany
State/province [32] 0 0
Erlangen
Country [33] 0 0
Germany
State/province [33] 0 0
Essen
Country [34] 0 0
Germany
State/province [34] 0 0
Hamburg
Country [35] 0 0
Germany
State/province [35] 0 0
Heidelberg
Country [36] 0 0
Germany
State/province [36] 0 0
Mainz
Country [37] 0 0
Hungary
State/province [37] 0 0
Budapest
Country [38] 0 0
Hungary
State/province [38] 0 0
Debrecen
Country [39] 0 0
Italy
State/province [39] 0 0
MI
Country [40] 0 0
Italy
State/province [40] 0 0
RM
Country [41] 0 0
Japan
State/province [41] 0 0
Aichi
Country [42] 0 0
Japan
State/province [42] 0 0
Hokkaido
Country [43] 0 0
Japan
State/province [43] 0 0
Kanagawa
Country [44] 0 0
Japan
State/province [44] 0 0
Kumamoto
Country [45] 0 0
Japan
State/province [45] 0 0
Okinawa
Country [46] 0 0
Japan
State/province [46] 0 0
Osaka
Country [47] 0 0
Korea, Republic of
State/province [47] 0 0
Seoul
Country [48] 0 0
Latvia
State/province [48] 0 0
Riga
Country [49] 0 0
Netherlands
State/province [49] 0 0
The Netherlands
Country [50] 0 0
Netherlands
State/province [50] 0 0
Groningen
Country [51] 0 0
Netherlands
State/province [51] 0 0
Rotterdam
Country [52] 0 0
Norway
State/province [52] 0 0
Oslo
Country [53] 0 0
Spain
State/province [53] 0 0
Catalunya
Country [54] 0 0
Spain
State/province [54] 0 0
Cataluña
Country [55] 0 0
Spain
State/province [55] 0 0
Islas Baleares
Country [56] 0 0
Spain
State/province [56] 0 0
Zaragoza
Country [57] 0 0
Sweden
State/province [57] 0 0
Göteborg
Country [58] 0 0
Sweden
State/province [58] 0 0
Uppsala
Country [59] 0 0
Switzerland
State/province [59] 0 0
Bern
Country [60] 0 0
United Kingdom
State/province [60] 0 0
Glasgow
Country [61] 0 0
United Kingdom
State/province [61] 0 0
London
Country [62] 0 0
United Kingdom
State/province [62] 0 0
Manchester

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to investigate the safety, efficacy, pharmacokinetics (PK) and
pharmacodynamics (PD) of three CFZ533 dose regimens in kidney transplant recipients.

This study will allow assessment of the ability of CFZ533 to replace Calcineurin inhibitors
(CNIs) in terms of anti-rejection efficacy, while providing better renal function with a
better safety and tolerability profile. Results of this study will be used to inform the
CFZ533 dose and regimen selection for investigation in later phases of clinical development.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03663335
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03663335